2'-O-methyl-1-β-D-lyxofuranosylcytosine | 65144-29-8

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: 2'-O-methyl-1-β-D-lyxofuranosylcytosine
• 英文别名: 2'-O-Methyl-1-β-D-lyxofuranosylcytosin；4-amino-1-(O²-methyl-β-D-lyxofuranosyl)-1H-pyrimidin-2-one；B-D-2'-methyl-cytidine；4-amino-1-[(2R,3S,4S,5R)-4-hydroxy-5-(hydroxymethyl)-3-methoxyoxolan-2-yl]pyrimidin-2-one
• CAS: 65144-29-8
• 化学式: C₁₀H₁₅N₃O₅
• 分子量: 257.246
• InChiKey: RFCQJGFZUQFYRF-RSWFSCQZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.6
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  118
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  重氮甲烷 、 1-β-D-lyxofuranosylcytosine 在 tin(ll) chloride 作用下， 以 甲醇 为溶剂， 生成 2',5'-di-O-methyl-1-β-D-lyxofuranosylcytosine 、 3'-O-methyl-1-β-D-lyxofuranosylcytosine 、 2'-O-methyl-1-β-D-lyxofuranosylcytosine 、 3',5'-di-O-methyl-1-β-D-lyxofuranosylcytosine
  参考文献：
  名称：

  氯化亚锡存在下重氮甲烷甲基化核苷糖羟基的机理

  摘要：

  摘要重氮甲烷与SnCl 2在甲醇中快速反应，生成MeCl和Sn（OMe）2，并进行了分离和鉴定。该反应是表观SnCl 2-2H 2 O重氮甲烷催化核苷甲基化的第一步。实际的催化剂Sn（OMe）2容易与布朗斯台德酸反应，交换配体。对于核呋喃糖基核苷，Sn 2+结合至具有不稳定质子的位点，其作用尤其主要是5元和6元环状结构，其中锡离子与糖部分的离子化羟基配位。这些环状结构说明了羟基对Me +的高反应性，就像核糖呋喃糖基核苷与Bu 2 SnO的配合物一样。在吡喃葡萄糖苷的情况下，类似的机制（如果不是相同的话）起作用。

  DOI：

  10.1016/s0008-6215(00)80988-x

文献信息

• Antiviral nucleosides
  申请人：Sarma Keshab

  公开号：US20070232562A1

  公开（公告）日：2007-10-04

  Compounds having the formula I wherein R 1 is as herein defined are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for inhibiting hepatitis replication, processes for making the compounds and synthetic intermediates used in the process

  具有公式I的化合物，其中R1如本文所定义，是丙型肝炎病毒NS5b聚合酶抑制剂。还公开了用于抑制肝炎复制的组合物和方法，制备化合物的工艺以及工艺中使用的合成中间体。
• Profiling chemically modified DNA/RNA units for disease and cancer diagnosis
  申请人：The Research Foundation for The State University of New York

  公开号：US11339441B2

  公开（公告）日：2022-05-24

  The present invention relates to high-throughput methods comprising direct infusion electrospray ionization mass spectrometry (ESI-MS), multistep tandem mass spectrometry (MSn), consecutive reaction monitoring (CRM), ion mobility spectrometry mass spectrometry (IMS-MS), high-resolution MS, and IMS-MS, for genome-wide (whole cell or tissue) profiling of DNA and RNA nucleotides/nucleosides having a wide variety of variant structural modifications. In particular, these methods are contemplated for providing a specific profile of variant DNA and/or RNA chemically modified nucleic acids (i.e. structures) associated with specific medical conditions. Medical conditions may include, but are not limited to: cancer; including prostate, lung, uterus, larynx, ovary, breast, kidney, and many other types of cancers; specific stages of cancer; bacterial infections; viral infections; genetic and metabolic disorders; and any condition involving changes in DNA and/or RNA structural modifications.

  本发明涉及高通量方法，包括直接注入电喷雾离子化质谱（ESI-MS）、多步串联质谱（MSn）、连续反应监测（CRM）、离子迁移谱质谱（IMS-MS）、高分辨率 MS 和 IMS-MS，用于对具有多种变异结构修饰的 DNA 和 RNA 核苷酸/核苷进行全基因组（全细胞或组织）分析。特别是，这些方法可用于提供与特定病症相关的变异 DNA 和/或 RNA 化学修饰核酸（即结构）的特定概况。病症可包括但不限于：癌症；包括前列腺癌、肺癌、子宫癌、喉癌、卵巢癌、乳腺癌、肾癌和许多其他类型的癌症；癌症的特定阶段；细菌感染；病毒感染；遗传和代谢紊乱；以及任何涉及 DNA 和/或 RNA 结构修饰变化的病症。
• 3',5'-DI-O-ACYLATED NUCLEOSIDES FOR HCV TREATMENT
  申请人：F.HOFFMANN-LA ROCHE AG

  公开号：EP2004634A1

  公开（公告）日：2008-12-24
• PROFILING CHEMICALLY MODIFIED DNA/RNA UNITS FOR DISEASE AND CANCER DIAGNOSIS
  申请人：THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK

  公开号：US20170044619A1

  公开（公告）日：2017-02-16

  The present invention relates to high-throughput methods comprising direct infusion electrospray ionization mass spectrometry (ESI-MS), multistep tandem mass spectrometry (MS n ), consecutive reaction monitoring (CRM), ion mobility spectrometry mass spectrometry (IMS-MS), high-resolution MS, and IMS-MS, for genome-wide (whole cell or tissue) profiling of DNA and RNA nucleotides/nucleosides having a wide variety of variant structural modifications. In particular, these methods are contemplated for providing a specific profile of variant DNA and/or RNA chemically modified nucleic acids (i.e. structures) associated with specific medical conditions. Medical conditions may include, but are not limited to: cancer; including prostate, lung, uterus, larynx, ovary, breast, kidney, and many other types of cancers; specific stages of cancer; bacterial infections; viral infections; genetic and metabolic disorders; and any condition involving changes in DNA and/or RNA structural modifications.
• US7645745B2
  申请人：——

  公开号：US7645745B2

  公开（公告）日：2010-01-12